Beta Bionics, Inc.
Close on Oct 19, 2026
- Market cap
- $750.14M
- P/E (TTM)
- –
- Dividend yield
- –
About Beta Bionics
Surgical & Medical Instruments & Apparatus, SIC 3841
Beta Bionics, Inc. is a medical technology company that develops and commercializes automated insulin delivery solutions for diabetes management. The company's primary commercial offering is the iLet, an automated insulin dosing system, alongside related single-use products and components. Its technology is designed for patients with type 1 diabetes, specifically cleared for adults and children aged six and older. The company distributes its medical devices and supplies to patients through healthcare channels, including durable medical equipment providers and pharmacy benefit plans.
The company conducts its commercial operations in the United States, where its primary device has received regulatory clearance. It maintains business relationships with multiple distributors across domestic channels to distribute its systems and consumable supplies. Beta Bionics is incorporated in Delaware and maintains its principal executive offices and corporate headquarters in Irvine, California.
Summary of the business section of Beta Bionics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Beta Bionics, Inc.
- Headquarters
- Irvine, CA
- Address
- 11 Hughes 92618
- Phone
- (949) 427-7785
- Website
- betabionics.com
- Employees
- 420, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- BBNX
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2025
- Shares outstanding
- 45M, Jul 27, 2026
- Public float
- $632.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1674632
- CUSIP
- 08659B102
- ISIN
- US08659B1026
- EIN
- 47-5386878
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean Saint | President & CEO, Director | 398,429 |
| Mark Hopman | Chief Commercial Officer | 88,033 |
| Mike Mensinger | Chief Product Officer | 177,390 |
| Steven Jon Russell | Chief Medical Officer | 207,699 |
| Stephen Feider | Chief Financial Officer | 159,378 |
| Christy Jones | Director | 19,564 |
| Danny L. Dearen | Director | 32,209 |
| Sean Carney | Director | 32,209 |
| Gerard J. Michel | Director | 33,509 |
| Maria Palasis | Director | 29,397 |
| Adam Lezack | Director | 27,399 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 420 full-time employees and three part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 31, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 27, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |